Cell therapy, now artisanal and costly, heads for mass production

October 12, 2018 by Bradley J. Fikes, The San Diego Union-Tribune

Not so long ago, manipulating living cells to serve as therapies was a difficult and mysterious art. Only a few biomedical companies and academic labs could claim proficiency.

But in recent years, there's been an explosion of knowledge about how work, how they can become diseased and how they can be cured. Three groundbreaking cell and gene therapy products have been approved since 2017; two for relapsing blood cancers, and one for a genetic disease that leads to blindness.

This transformation attracted nearly 70 presenting companies to La Jolla, Calif., for this year's Cell & Gene Meeting on the Mesa, an annual conference in the field.

These treatments are now costly and performed for a small number of patients. But scaling up this artisanal industry through mass production is expected to reduce costs and bring the benefits to many more people.

To prepare for this wave of cell therapies, the U.S. Food and Drug Administration has been updating its standards for assessing therapies, standards developed for pills and injections of drugs, not of living cells.

"It's the nature of this whole meeting that the process of characterizing something as squishy and variable as human biology, packaging it and heading toward the clinic, is cutting-edge for the FDA," said Taylor Crouch, CEO of San Diego's Organovo.

Organovo made a name for itself by selling "bioprinted" for toxicology screening of potential drugs. The San Diego is preparing to take its technology to patients with end-stage liver disease, Crouch said.

The company collects cells from donor livers, and prints them with a device that arrays the cells into a three-dimensional form, with various cells that support each other, Crouch said.

Transplanted liver cells could supplement function of a diseased liver until a donor liver can be found or perhaps even help the patient's own liver recover, Crouch said.

The company plans to file in 2020 to begin clinical testing, Crouch said.

Another presenting company, Athersys, is in late-stage or Phase 3 clinical testing of its cell therapy for strokes caused by blood clots. The product, called MultiStem, consists of cells taken from a donor's bone marrow, grown in the lab and frozen. When needed, they are thawed and then infused into a patient, said Gil Van Bokkelen, chairman and CEO of the Cleveland-based company.

MultiStem consists of a class of cells that reproduce prolifically in the lab, so the cells from one donor can yield "millions of clinical doses," he said. These cells reduce inflammation, promote regeneration, and are tolerated by the patient's immune system, Van Bokkelen said.

"We can administer them just like Type O blood," he said.

San Diego's ViaCyte is clinically testing a cell therapy for type 1 diabetes. The San Diego company's product replaces insulin-producing pancreatic "beta" cells, which are destroyed in the disease.

ViaCyte turns into precursors of these . These cells are then encapsulated in a device that is implanted into patients. The company is testing two variants of this approach.

Early human testing of one approach, using cells shielded by a semi-permeable membrane, hit a roadblock when the devices caused growth of fibrous tissue. This blocked diffusion of insulin into the patient. Testing has been suspended while ViaCyte reworks the encapsulating material, with help from W.L. Gore & Associates, the makers of Gore-Tex.

That trial is expected to be restarted next year once approval is granted, said Paul Laikind, ViaCyte's CEO.

Meanwhile, ViaCyte has advanced development of a somewhat different device, which allows direct contact between the cells and patient tissue. This risks an immune reaction, so receiving the devices must take immune-suppressing drugs.

So far, side effects have been like those expected from taking immune-suppressing drugs, and appear controllable, Laikind said. But it's too early to know if the cells can produce therapeutic quantities of insulin.

Patients and others looking for more information on clinical trials from these companies can search for the name of the company on www.clinicaltrials.gov .

Explore further: As stem cell and gene technologies advance, La Jolla conference mushrooms


Related Stories

As stem cell and gene technologies advance, La Jolla conference mushrooms

October 4, 2018
In 2006, a few hundred mostly local researchers gathered in La Jolla to discuss the emerging but still science-fictiony field of stem cells.

Johnson & Johnson, ViaCyte testing possible diabetes cure

February 4, 2016
Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder.

Unique pancreatic stem cells have potential to regenerate beta cells, respond to glucose

February 27, 2018
Scientists from the Diabetes Research Institute at the University of Miami Miller School of Medicine have confirmed the existence of progenitor cells within the human pancreas that can be stimulated to develop into glucose-responsive ...

'Educating' patients' immune cells may help combat diabetes

July 7, 2017
New research reveals that a treatment called Stem Cell Educator therapy is safe and effective for treating type 1 and type 2 diabetes. The therapy cultures the patient's immune cells with cord blood stem cells and returns ...

Organovo announces ability to print 3D human liver tissue

April 24, 2013
(Medical Xpress)—Organovo Holdings, Inc., a company that designs and creates functional human tissue has announced at this year's Experimental Biology Conference that it has developed a 3D printing technique that is able ...

Beta cell-seeded implant restores insulin production in type 1 diabetes mouse model

March 19, 2018
Researchers have successfully created a novel biomaterial that can be seeded with insulin-producing beta cells. Implantation of the beta cell-seeded biomaterial reversed diabetes in a mouse model by effectively normalizing ...

Recommended for you

How do babies laugh? Like chimps!

November 7, 2018
Few things can delight an adult more easily than the uninhibited, effervescent laughter of a baby. Yet baby laughter, a new study shows, differs from adult laughter in a key way: Babies laugh as they both exhale and inhale, ...

Tongue-in-cheek Nobels honor nutritional analysis of cannibalism, roller-coaster kidney stones treatment

September 14, 2018
A nutritional analysis of cannibalism and treating kidney stones on roller-coasters were research projects honored by tongue-in-cheek awards at Harvard University Thursday, designed to make you laugh first, and think later.

Pediatric robot patient offers new level of realism for doctors in training

September 10, 2018
A team of researchers and engineers at Gaumard Scientific has unveiled a new robot that raises the bar on medical training devices. The robot, called HAL, has been made to look like a five-year-old male patient and offers ...

Why men say they've had more lifetime sexual partners than women

July 25, 2018
The disparity between the number of sexual partners reported by men and women can largely be explained by a tendency among men to report extreme numbers of partners, and to estimate rather than count their lifetime total, ...

Censors jump into action as China's latest vaccine scandal ignites

July 22, 2018
Chinese censors on Sunday deleted articles and postings about the vaccine industry as an online outcry over the country's latest vaccine scandal intensified.

Revenge of a forgotten medical 'genius'

June 30, 2018
It's not an uncommon fate for a pioneering scientist: languishing unrecognised in his time before dying in obscurity. But as his 200th birthday approaches, the life-saving work of a Hungarian obstetrician is finally getting ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.